Leerink Partnrs Has Bearish Estimate for UTHR Q2 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Investment analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for shares of United Therapeutics in a research note issued on Thursday, February 27th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will earn $6.99 per share for the quarter, down from their previous estimate of $7.31. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.94 EPS, Q4 2025 earnings at $8.32 EPS, FY2025 earnings at $29.43 EPS and FY2028 earnings at $32.33 EPS.

A number of other research analysts have also issued reports on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Trading Down 0.5 %

Shares of United Therapeutics stock opened at $308.59 on Monday. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The firm has a market capitalization of $13.86 billion, a price-to-earnings ratio of 13.55, a PEG ratio of 0.97 and a beta of 0.57. The firm’s 50 day simple moving average is $357.53 and its two-hundred day simple moving average is $360.79.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business posted $4.36 EPS.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $929,678.52. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 124,164 shares of company stock valued at $45,278,893. Corporate insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Siemens Fonds Invest GmbH acquired a new stake in shares of United Therapeutics during the fourth quarter valued at about $162,000. Park Square Financial Group LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $217,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $16,505,000. Polar Asset Management Partners Inc. purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $7,798,000. Finally, Forum Financial Management LP boosted its stake in shares of United Therapeutics by 4.5% in the fourth quarter. Forum Financial Management LP now owns 1,313 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 57 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.